Literature DB >> 8795746

An endothelin-1-induced model of chronic optic nerve ischemia in rhesus monkeys.

S Orgül1, G A Cioffi, D R Bacon, E M Van Buskirk.   

Abstract

PURPOSE: The purpose of this study was to evaluate flow reduction to the optic nerve after chronic administration of endothelin-1 in primates.
MATERIALS AND METHODS: Endothelin-1 (three rhesus monkeys), in a dosage of 0.1 microgram/day, or balanced salt solution (three rhesus monkeys) was delivered to the perineural region of the anterior optic nerve via osmotically driven minipumps. Optic nerve blood flow was determined by means of a colored microspheres technique after 7 days of local endothelin-1 or balanced salt solution administration. The effect of endothelin-1 on optic nerve blood flow was analyzed by analysis of convariance (ANCOVA) in a 2 (between groups: endothelin-1, balanced salt solution) x 2 (within subject: blood flow minipump optic nerve, blood flow controls) design, with intraocular pressure as a changing covariate.
RESULTS: The decrease of optic nerve blood flow in the endothelin-1 eyes was significant compared to the balanced salt solution eyes (ANCOVA p = 0.015). Among the monkeys implanted with endothelin-1 minipumps, the decrease in optic nerve blood flow in the experimental eye compared to the contralateral eye (mean +/- SD 35.7 +/- 9.1%) was significant (p = 0.01), while that among the monkeys implanted with balanced salt solution minipumps (mean +/- SD 0.7 +/- 5.5%) was not (p = 0.73).
CONCLUSIONS: This new primate model of chronic optic nerve ischemia may represent a method to evaluate experimentally the implication of a local hemodynamic perturbation in various optic neuropathies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8795746

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  20 in total

1.  Factors affecting the use of multifocal electroretinography to monitor function in a primate model of glaucoma.

Authors:  Brad Fortune; Grant Cull; Lin Wang; E Michael Van Buskirk; George A Cioffi
Journal:  Doc Ophthalmol       Date:  2002-09       Impact factor: 2.379

Review 2.  A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma.

Authors:  Claude F Burgoyne
Journal:  Exp Eye Res       Date:  2010-09-16       Impact factor: 3.467

3.  The non-human primate experimental glaucoma model.

Authors:  Claude F Burgoyne
Journal:  Exp Eye Res       Date:  2015-06-09       Impact factor: 3.467

Review 4.  Endothelin antagonism as an active principle for glaucoma therapy.

Authors:  Rita Rosenthal; Michael Fromm
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

5.  Endothelin-Mediated Changes in Gene Expression in Isolated Purified Rat Retinal Ganglion Cells.

Authors:  Shaoqing He; Yong H Park; Thomas Yorio; Raghu R Krishnamoorthy
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09-01       Impact factor: 4.799

Review 6.  Targets of Neuroprotection in Glaucoma.

Authors:  Shaoqing He; Dorota L Stankowska; Dorette Z Ellis; Raghu R Krishnamoorthy; Thomas Yorio
Journal:  J Ocul Pharmacol Ther       Date:  2017-08-18       Impact factor: 2.671

7.  Ischemic model of optic nerve injury.

Authors:  George A Cioffi
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 8.  Ischemic optic neuropathies and their models: disease comparisons, model strengths and weaknesses.

Authors:  Steven L Bernstein; Neil R Miller
Journal:  Jpn J Ophthalmol       Date:  2015-02-18       Impact factor: 2.447

9.  Effects of endothelin-1 on calcium-independent contraction of bovine trabecular meshwork.

Authors:  Giulia Renieri; Lars Choritz; Rita Rosenthal; Susann Meissner; Norbert Pfeiffer; Hagen Thieme
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-10       Impact factor: 3.117

Review 10.  Solving the lost in translation problem: improving the effectiveness of translational research.

Authors:  Ceren Ergorul; Leonard A Levin
Journal:  Curr Opin Pharmacol       Date:  2012-09-11       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.